Literature DB >> 30715570

Clinical characteristics and prognostic factors in acute coronary syndrome patients complicated with cardiogenic shock in Japan: analysis from the Japanese Circulation Society Cardiovascular Shock Registry.

Kazuo Sakamoto1,2, Tetsuya Matoba3,4, Masahiro Mohri1,5, Yasushi Ueki1,6, Yasuyuki Tsujita1,7, Masao Yamasaki1,8, Nobuhiro Tanaka1,9, Yohei Hokama1,9, Motoki Fukutomi1,10, Katsutaka Hashiba1,11, Rei Fukuhara1,12, Satoru Suwa1,13, Hirohide Matsuura1,14, Eizo Tachibana1,15, Naohiro Yonemoto1,16, Ken Nagao1,17.   

Abstract

Cardiogenic shock frequently leads to death even with intensive treatment. Although the leading cause of cardiogenic shock is acute coronary syndrome (ACS), the clinical characteristics and the prognosis of ACS with cardiogenic shock in the present era still remain to be elucidated. We analyzed clinical characteristics and predictors of 30-day mortality in ACS with cardiogenic shock in Japan. The Japanese Circulation Society Cardiovascular Shock registry was a prospective, observational, multicenter, cohort study. Between May 2012 and June 2014, 495 ACS patients with cardiogenic shock were analyzed. The primary endpoint was 30-day all-cause mortality. The median [interquartile range; IQR] age was 71.0 [63.0, 80.0] years. The median [IQR] value of systolic blood pressure (SBP) and heart rate were 75.0 [50.0, 86.5] mm Hg and 65.0 [38.0, 98.0] bpm, respectively. Multivariable analysis showed an odds ratio (OR) of 4.76 (confidence intervals; CI 1.97-11.5, p < 0.001) in the lowest SBP category (< 50 mm Hg) for SBP ≥ 90 mm Hg. Moreover, age per 10 years increase (OR 1.38, CI 1.18-1.61, p = 0.002), deep coma (OR 3.49, CI 1.94-6.34, p < 0.001), congestive heart failure (OR 3.81, CI 2.04-7.59, p < 0.001) and left main trunk disease (LMTD) (OR 2.81, CI 1.55-5.10, p < 0.001) were independent predictors. Severe hypotension, older age, deep coma, congestive heart failure, and LMTD were independent unfavorable factors in ACS complicated by cardiogenic shock in Japan. A prompt assessment of high-risk patients referring to those predictors in emergency room could lead to appropriate treatment without delay.

Entities:  

Keywords:  Acute coronary syndrome; Cardiogenic shock; Mortality; Prognostic factors

Mesh:

Year:  2019        PMID: 30715570     DOI: 10.1007/s00380-019-01354-9

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  32 in total

1.  Nationwide public-access defibrillation in Japan.

Authors:  Tetsuhisa Kitamura; Taku Iwami; Takashi Kawamura; Ken Nagao; Hideharu Tanaka; Atsushi Hiraide
Journal:  N Engl J Med       Date:  2010-03-18       Impact factor: 91.245

Review 2.  Cardiogenic shock: current concepts and improving outcomes.

Authors:  Harmony R Reynolds; Judith S Hochman
Journal:  Circulation       Date:  2008-02-05       Impact factor: 29.690

3.  Emergency percutaneous coronary intervention in patients with ST-elevation myocardial infarction complicated by out-of-hospital cardiac arrest: early and medium-term outcome.

Authors:  Corrado Lettieri; Stefano Savonitto; Stefano De Servi; Giulio Guagliumi; Guido Belli; Alessandra Repetto; Emanuela Piccaluga; Alessandro Politi; Federica Ettori; Battistina Castiglioni; Franco Fabbiocchi; Nicoletta De Cesare; Giuseppe Sangiorgi; Giuseppe Musumeci; Marco Onofri; Maurizio D'Urbano; Salvatore Pirelli; Roberto Zanini; Silvio Klugmann
Journal:  Am Heart J       Date:  2008-12-20       Impact factor: 4.749

4.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Authors:  J S Hochman; L A Sleeper; J G Webb; T A Sanborn; H D White; J D Talley; C E Buller; A K Jacobs; J N Slater; J Col; S M McKinlay; T H LeJemtel
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

5.  One-year survival following early revascularization for cardiogenic shock.

Authors:  J S Hochman; L A Sleeper; H D White; V Dzavik; S C Wong; V Menon; J G Webb; R Steingart; M H Picard; M A Menegus; J Boland; T Sanborn; C E Buller; S Modur; R Forman; P Desvigne-Nickens; A K Jacobs; J N Slater; T H LeJemtel
Journal:  JAMA       Date:  2001-01-10       Impact factor: 56.272

6.  Ten-year trends in the incidence and treatment of cardiogenic shock.

Authors:  Raban V Jeger; Dragana Radovanovic; Patrick R Hunziker; Matthias E Pfisterer; Jean-Christophe Stauffer; Paul Erne; Philip Urban
Journal:  Ann Intern Med       Date:  2008-11-04       Impact factor: 25.391

7.  Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial.

Authors:  John G Webb; April M Lowe; Timothy A Sanborn; Harvey D White; Lynn A Sleeper; Ronald G Carere; Christopher E Buller; S Chiu Wong; Jean Boland; Vlad Dzavik; Mark Porway; Gordon Pate; Geoffrey Bergman; Judith S Hochman
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

8.  Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention.

Authors:  Rajendra H Mehta; Fang-Shu Ou; Eric D Peterson; Richard E Shaw; William B Hillegass; John S Rumsfeld; Matthew T Roe
Journal:  JACC Cardiovasc Interv       Date:  2009-01       Impact factor: 11.195

9.  Predictors of hospital mortality in the global registry of acute coronary events.

Authors:  Christopher B Granger; Robert J Goldberg; Omar Dabbous; Karen S Pieper; Kim A Eagle; Christopher P Cannon; Frans Van De Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Keith A A Fox
Journal:  Arch Intern Med       Date:  2003-10-27

10.  Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).

Authors:  Uwe Zeymer; Albrecht Vogt; Ralf Zahn; Michael A Weber; Ulrich Tebbe; Martin Gottwik; Tassilo Bonzel; Jochen Senges; Karl-Ludwig Neuhaus
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.